Cellebrite DI Gestione
Criteri Gestione verificati 1/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Shiv Ramji
Amministratore delegato
n/a
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | less than a year |
| Proprietà del CEO | n/a |
| Durata media del management | 1.2yrs |
| Durata media del Consiglio di amministrazione | 5.1yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento narrativa • Sep 03
CLBT: AI Evidence Platform And Cloud Risks Will Shape Future Earnings Power
Analysts have trimmed the Cellebrite DI fair value estimate to $12.50 from $15.00. This reflects updated views on slower revenue growth, slightly lower discount rates, improved profit margin assumptions, and a reset in future P/E expectations following reduced revenue guidance and longer sales cycles cited in recent research.Seeking Alpha • Sep 02
Cellebrite: Mobile Forensics Leadership At A Compelling Valuation
Summary Cellebrite offers ~90% recurring revenue and 117% net retention, anchored by mobile forensics leadership and new growth levers. Cellebrite is rated 'Buy' at ~$12, with a Fair Value estimate of $17.3, reflecting ~44% potential upside and a strong GARP profile. I see a narrow moat based on their leadership in mobile forensics, robust rule of X score, and cross-selling opportunities. Risks include quantum disruption, geopolitical exposure in Israel, and device maker advances; conservative scenarios suggest the current valuation is fair. Read the full article on Seeking Alpha
Aggiornamento narrativa • Aug 14
CLBT: Federal AI And Cloud Demand Will Support Premium Future P/E Potential
Cellebrite DI's analyst price target has shifted lower from about $21 to roughly $15, as analysts factor in the new CEO appointment, reduced 2026 revenue guidance, softer ARR trends, and longer sales cycles highlighted in recent research updates. Analyst Commentary Recent research on Cellebrite DI highlights a mixed setup.Articolo di analisi • Jun 20
Cellebrite DI (CLBT) Stock Could Be 23% Undervalued After Genesis AI Launch
Cellebrite DI (NasdaqGS:CLBT) is drawing fresh attention after announcing general availability of Cellebrite Genesis, an AI-driven digital evidence tool that early law enforcement users report is reshaping how complex investigations are handled. See our latest analysis for Cellebrite DI. The Cellebrite DI share price has pulled back in recent months, with a 90 day share price return of 10.09% and a year to date share price return of 28.08% in the red. However, the 3 year total shareholder...Aggiornamento narrativa • Jun 19
CLBT: AI Evidence Platform And Cloud Authorizations Will Shape Earnings Power
Analysts have adjusted the Cellebrite DI price target from $18 to $15, citing updated views on valuation multiples, while still highlighting a large and growing addressable market and multiple drivers for recurring revenue growth. Analyst Commentary on Cellebrite DI Recent research on Cellebrite DI reflects a mix of optimism about the company's addressable market and recurring revenue potential, alongside a more cautious stance on valuation.Aggiornamento narrativa • Jun 04
CLBT: Federal AI And Cloud Adoption Will Support Premium P/E Potential
Analysts have nudged the fair value estimate for Cellebrite DI slightly lower from $21.67 to $21.00, tying this adjustment to modestly revised assumptions for revenue growth, profit margins, and future P/E multiples, following recent research that highlights both multiple compression and a large, growing addressable market. Analyst Commentary Recent research highlights a mix of optimism and caution on Cellebrite DI, with views anchored in the size of the opportunity, the pace of recurring revenue growth, and the impact of multiple compression on valuation.Aggiornamento narrativa • May 19
CLBT: Multiple Compression And Cloud Wins Will Shape Medium Term Earnings Power
Cellebrite DI’s analyst price target has been revised from $23 to $15, as analysts factor in multiple compression alongside updated assumptions for the discount rate, revenue growth, profit margin, and forward P/E. Analyst Commentary Bearish analysts have trimmed price targets on Cellebrite DI, highlighting concerns that the stock’s prior valuation left limited room for error even as quarterly results compared well with consensus expectations.Aggiornamento narrativa • Apr 22
CLBT: Updated Risk Profile And 2026 Guidance Will Support Premium P/E Potential
Analysts have trimmed their price targets on Cellebrite DI by $2. This reflects updated views on the stock's risk profile and valuation assumptions, while core growth and margin expectations remain largely unchanged.Aggiornamento narrativa • Apr 07
CLBT: Updated Modeling And 2026 Guidance Will Support Premium P/E Potential
Cellebrite DI's analyst price targets have been trimmed by $2, with analysts linking the adjustment to updated assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts trimming their price targets by $2 are tying the move to refreshed views on discount rates, long term revenue growth, profit margins, and future P/E assumptions, rather than a single company specific event.Aggiornamento narrativa • Mar 24
CLBT: Refined Modeling And 2026 Guidance Will Support Premium P/E Potential
Analysts trimmed their price targets for Cellebrite DI by $2 to $21.67, citing updated assumptions on discount rate, long term revenue growth, profit margin and future P/E. These changes keep fair value broadly unchanged while slightly adjusting the risk and return profile.Aggiornamento narrativa • Mar 09
CLBT: 2026 Revenue Guidance Will Support Earnings Power Despite P/E Recalibration
Analysts have trimmed their price targets on Cellebrite DI by $2, reflecting updated views on the stock's future P/E multiple and risk profile, while keeping key growth and profitability assumptions largely unchanged. Analyst Commentary Recent research updates suggest that analysts are adjusting their views on Cellebrite DI more around valuation mechanics than around its underlying business assumptions.Aggiornamento narrativa • Feb 23
CLBT: Sustained Margins And 2026 Guidance Will Support Earnings Power
Analysts have adjusted their average price target on Cellebrite DI to about $21.67, down from the previous $24.71 level. The revised target reflects updated views on fair value, profit margins and future P/E assumptions following recent research updates from multiple firms.Aggiornamento narrativa • Feb 08
CLBT: Higher Profitability Assumptions Will Support Stronger Medium Term Earnings Power
Analysts have raised their price target on Cellebrite DI from US$18.00 to US$23.00, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E as the key drivers of the change. What's in the News Cellebrite DI issued earnings guidance for the fourth quarter of 2025, with expected revenue between US$123 million and US$128 million and annual growth guidance of 13% to 17% (company guidance).Aggiornamento narrativa • Jan 25
CLBT: Sustained Margins And 2025 ARR Guidance Will Support Earnings Power
Analysts have maintained their price target on Cellebrite DI at US$24.71, with only minor tweaks to inputs such as the discount rate and forward P/E, reflecting stable expectations around revenue growth and profit margin assumptions. What's in the News Cellebrite DI issued earnings guidance for the fourth quarter of 2025, targeting revenue of US$123 million to US$128 million, with annual growth of 13% to 17% (company guidance).Articolo di analisi • Jan 13
Cellebrite DI Ltd.'s (NASDAQ:CLBT) Shareholders Might Be Looking For Exit
With a price-to-sales (or "P/S") ratio of 9.7x Cellebrite DI Ltd. ( NASDAQ:CLBT ) may be sending very bearish signals...Aggiornamento narrativa • Jan 10
CLBT: Sustained Margin Strength Will Support Future Earnings Power
Analysts have maintained their fair value estimate for Cellebrite DI at US$24.71, making only minor adjustments to inputs such as the discount rate and long term P/E assumptions. This reflects a view that recent information does not materially alter their price outlook.Aggiornamento narrativa • Dec 24
CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead
Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, citing incremental improvements in the company’s discount rate assumptions and sustained expectations for high revenue growth and robust profit margins. What's in the News Cellebrite DI issued fourth quarter 2025 revenue guidance of $123 million to $128 million, implying year over year growth of 13% to 17% (company guidance).Aggiornamento narrativa • Dec 10
CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead
Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, reflecting slightly higher long term revenue growth and profit margin expectations that more than offset a marginally higher assumed discount rate and a modestly lower future P/E multiple. What's in the News Cellebrite DI issued revenue guidance for the fourth quarter of 2025, projecting between $123 million and $128 million, representing annual growth of 13% to 17% (company guidance).Aggiornamento narrativa • Nov 26
CLBT: Profit Margins Will Drive Improved Earnings Outlook Into Next Year
Analysts have raised their price target for Cellebrite DI from $23.14 to $24.71. This change reflects increased confidence in the company’s stronger profit margins and revenue growth outlook.Aggiornamento narrativa • Sep 23
Cloud SaaS Solutions Will Drive Digital Forensics Adoption
Cellebrite DI’s consensus price target was modestly raised to $23.14 as analysts anticipate near-term revenue softness due to U.S. federal budget constraints and delayed deal timing, while seeing future upside from eventual deal catch-up and FedRAMP progress. Analyst Commentary Slower-moving Q1 deals in Europe were completed in Q2, but persistent softness in U.S. federal deals is expected to continue until at least October, impacting near-term revenue.Articolo di analisi • Sep 09
What Cellebrite DI Ltd.'s (NASDAQ:CLBT) 26% Share Price Gain Is Not Telling You
Cellebrite DI Ltd. ( NASDAQ:CLBT ) shareholders would be excited to see that the share price has had a great month...Articolo di analisi • Aug 18
Earnings Beat: Cellebrite DI Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
NasdaqGS:CLBT 1 Year Share Price vs Fair Value Explore Cellebrite DI's Fair Values from the Community and select yours...Aggiornamento narrativa • Aug 15
Cloud SaaS Solutions Will Drive Digital Forensics Adoption
Cellebrite DI’s consensus price target held steady at $23.00 as analysts factor in near-term headwinds from delayed federal spending and efficiency impacts, yet remain positive about long-term growth driven by healthy demand and anticipated federal certifications. Analyst Commentary Lowered Q2 results and second half guidance due to ongoing efficiency impacts and customer budget pauses.AMMINISTRATORE DELEGATO
Shiv Ramji
less than a year
Mandato
Mr. Shiven Ramji, also known as Shiv, was President of Products & Technology of Cellebrite DI Ltd. from May 4, 2026 to August 13, 2026 and serves as CEO & Director since August 13, 2026. He was President o...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chief Financial Officer | 1.2yrs | US$1.89m | 0.13% $ 3.9m | |
| Advisor | less than a year | US$10.80m | 0.31% $ 8.9m | |
| Global Chief Revenue Officer | 2.8yrs | US$2.38m | 0.049% $ 1.4m | |
| CEO & Director | less than a year | Nessun dato | Nessun dato | |
| Chief Technology Officer | less than a year | Nessun dato | 0.24% $ 7.1m | |
| Chief Information Officer | 2.1yrs | Nessun dato | 0.033% $ 961.4k | |
| VP of Investor Relations & Treasury | no data | Nessun dato | Nessun dato | |
| General Counsel & Chief Compliance Officer | less than a year | Nessun dato | 0.038% $ 1.1m | |
| Chief Marketing Officer | 2.5yrs | Nessun dato | 0% $ 0 | |
| Chief People Officer | 3.7yrs | Nessun dato | 0.052% $ 1.5m | |
| Head of AI Innovation | no data | Nessun dato | Nessun dato |
1.2yrs
Durata media
56yo
Età media
Gestione esperta: Il team dirigenziale di CLBT non è considerato esperto (durata media 1.2 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | less than a year | Nessun dato | Nessun dato | |
| Lead Independent Director | 1.7yrs | Nessun dato | 0.0071% $ 206.9k | |
| Independent External Director | 5.1yrs | Nessun dato | 0.011% $ 324.3k | |
| Independent Chairman | 5.1yrs | Nessun dato | 0.32% $ 9.4m | |
| Independent Director | 2.1yrs | Nessun dato | 0.0084% $ 243.6k | |
| Independent Director | 3.3yrs | Nessun dato | 0.014% $ 413.2k | |
| Independent External Director | 5.1yrs | Nessun dato | 0.014% $ 413.2k | |
| Independent Director | 6.4yrs | Nessun dato | 0.024% $ 706.4k | |
| Independent Director | 6.4yrs | Nessun dato | 0.016% $ 474.1k | |
| Advisory Board Member | no data | Nessun dato | Nessun dato |
5.1yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CLBT sono considerati esperti (durata media dell'incarico 5.1 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/21 08:19 |
| Prezzo dell'azione a fine giornata | 2026/09/21 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Cellebrite DI Ltd. è coperta da 10 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Tyler Radke | Citigroup Inc |
| Jeffrey Van Rhee | Craig-Hallum Capital Group LLC |
| Rudy Kessinger | D.A. Davidson & Co. |